Merus N.V. (MRUS)
NASDAQ: MRUS · Real-Time Price · USD
44.61
-0.22 (-0.49%)
At close: Mar 28, 2025, 4:00 PM
44.01
-0.60 (-1.34%)
After-hours: Mar 28, 2025, 5:31 PM EDT
Merus Employees
As of December 31, 2024, Merus had 321 total employees, including 260 full-time and 61 part-time employees. The number of employees increased by 92 or 40.17% compared to the previous year.
Employees
321
Change (1Y)
92
Growth (1Y)
40.17%
Revenue / Employee
$112,564
Profits / Employee
-$670,798
Market Cap
3.08B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
MRUS News
- 4 weeks ago - Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Merus to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma - GlobeNewsWire
- 6 weeks ago - Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit - GlobeNewsWire
- 7 weeks ago - New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer - GlobeNewsWire
- 2 months ago - Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff - Seeking Alpha
- 2 months ago - Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs - GlobeNewsWire
- 3 months ago - Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC - GlobeNewsWire